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Background: Peptides derived from the C-terminal heptad repeat (CHR) of HIV-1 gp41 such as T20 (Enfuvirtide)
and C34 are potent viral fusion inhibitors. We have recently found that two N-terminal residues (Met115 and
Thr116) of CHR peptides form a unique M-T hook structure that can greatly enhance the binding and anti-HIV
activity of inhibitors. Here, we applied two M-T hook residues to optimize SC29EK, an electrostatically constrained
peptide inhibitor with a potent anti-HIV activity.
Results: The resulting peptide MT-SC29EK showed a dramatically increased binding affinity and could block the
six-helical bundle (6-HB) formation more efficiently. As expected, MT-SC29EK potently inhibited HIV-1 entry and
infection, especially against those T20- and SC29EK-resistant HIV-1 variants. More importantly, MT-SC29EK and its
short form (MT-SC22EK) suffered from the difficulty to induce HIV-1 resistance during the in vitro selection,
suggesting their high genetic barriers to the development of resistance.
Conclusions: Our studies have verified the M-T hook structure as a vital strategy to design novel HIV-1 fusion
inhibitors and offered an ideal candidate for clinical development.
Keywords: HIV-1, Fusion inhibitor, M-T hook structure, ResistanceBackground
Entry of HIV-1 into target cells is mediated by its trimeric
envelope (Env) glycoprotein gp120/gp41 complex and in-
cludes two major steps [1,2]. First, the surface subunit
gp120 binds sequentially to the cell receptor and a core-
ceptor (CCR5 or CXCR4). Second, the transmembrane
subunit gp41 (Figure 1) inserts its fusion peptide (FP) into
the cell membrane and then packs its three C-terminal
heptad repeat region (CHR) onto three N-terminal heptad
repeat region (NHR) to form a six-helical bundle (6-HB)
structure that bridges the viral and cellular membranes
into a close proximity for fusion. Different from other
classes of anti-HIV drugs such as inhibitors of reverse
transcriptase and protease that act after infection occurs,
HIV-1 entry inhibitors intercept the virus before it invades
the target cells. Currently, there are two HIV-1 entry* Correspondence: yhe@ipb.pumc.edu.cn
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unless otherwise stated.inhibitors for clinical use: Maraviroc binds to the cell core-
ceptor CCR5 thus blocking the binding of virus [3,4];
Enfuvirtide (T20), a 36-amino acid peptide derived from
the gp41 CHR, binds competitively to the NHR thus pre-
venting the formation of 6-HB core [5-7]. Approved in
April 2003, T20 is the first and only HIV-1 fusion inhibitor
used in clinic but it requires a high dosage and easily in-
duces drug-resistance [8-11], calling for new strategies and
concepts for the development of next-generation drugs
targeting HIV fusion.
The crystal structure of 6-HB core reveals a deep
hydrophobic pocket on the C-terminal portion of NHR
trimer, which is inserted by three hydrophobic residues
from the pocket-binding domain (PBD) of CHR [12-14].
It is believed that the pocket critically determines the
stability of NHR-CHR interaction and can serve as an
ideal target for inhibitors [15,16]. Due to the lack of the
pocket-binding sites by T20, the CHR-derived peptide
C34 has been widely used as a template for peptide
engineering [17-19]. As a key strategy, the salt-bridge
structures were introduced into C34 sequence creatingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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T20                    YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF
C34          WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL
T1249        WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWEWF
SFT SWETWEREIENYTRQIYRILEESQEQQDRNERDLLE
CP32M VEWNEMTWMEWEREIENYTKLIYKILEESQEQ
T2635      TTWEAWDRAIAEYAARIEALIRAAQEQQEKNEAALREL
SC34EK       WZEWDRKIEEYTKKIEELIKKSQEQQEKNEKELK
SC29EK       WEEWDKKIEEYTKKIEELIKKSEEQQKKN
SC22EK       WEEWDKKIEEYTKKIEELIKKS
MT-SC22EK  MTWEEWDKKIEEYTKKIEELIKKS
MT-SC29EK  MTWEEWDKKIEEYTKKIEELIKKSEEQQKKN
Figure 1 Schematic diagram of HIV-1 gp41 and sequences of NHR or CHR-derived peptides. The gp41 numbering of HIV-1HXB2 is used. FP,
fusion peptide; NHR, N-terminal heptad repeat; CHR, C-terminal heptad repeat; TM, transmembrane domain; CT, cytoplasmic tail. The sequences
corresponding to the NHR pocket region are marked in blue; The sequences corresponding to the CHR pocket-binding domain are marked in
red; The position and sequence for the M-T hook structure are marked in green. Z in the SC34EK sequence indicates an artificial amino acid,
norleucine. The possible electrostatic interactions are indicated by lines and correlating amino acids.
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[20], T2635 [21] and Sifuvirtide (SFT) [22], in which the
amino acids at the solvent-accessible sites of helical bundle
were replaced with glutamate (E) and lysine (K) and those
at the NHR-interactive sites were maintained, thus in an
α-helical heptad repeat residues separated by three posi-
tions (i versus i + 4) were closely positioned in space on
the same site of the helix (Figure 1). As compared to C34,
these electrostatically-engineered inhibitors possessed the
significantly improved anti-HIV profiles [20-22]. By trun-
cating the C-terminus of SC34EK, the relatively short pep-
tide SC29EK was generated with a comparable anti-HIV
activity but its further truncation (SC22EK) could not be
tolerated [20]. Recently, we discovered that two residues
(Met115 and Thr116) preceding the pocket-binding do-
main of CHR peptides adopt a unique M-T hook structure
that can greatly enhance the pocket-binding [23]. Indeed,
the M-T hook structure-modified C34 and SC22EK exhib-
ited the dramatically increased binding affinity and anti-
viral activity [24,25], suggesting a totally new strategy for
designing or optimizing HIV-1 fusion inhibitors. In this
study, we applied two hook residues to modify SC29EK
and observed a significant optimization. Importantly, the
resulting peptide MT-SC29EK showed a highly improved
potency to inhibit T20- and SC29EK-resistant HIV-1 vari-
ants and a higher genetic barrier to resistance. Our studieshave validated a general feature of the M-T hook structure
for designing HIV-1 fusion inhibitors and offered a prom-
ising candidate for future development.
Results
The M-T hook residues dramatically enhance the stability
of 6-HB core
To validate a general role of the M-T hook structure and
develop a more active HIV-1 fusion inhibitor, we generated
the peptide MT-SC29EK by adding the residues methio-
nine (Met115) and thronine (Thr116) into the N-terminus
of SC29EK. The CD spectroscopy was first applied to
determine whether two hook residues can enhance the
α-helicity and thermal stability of the 6-HB structure. A
CHR peptide (C34, SC29EK or MT-SC29EK) was mixed
with the NHR peptide N36 at equal molar concentra-
tions and incubated at 37°C for 30 min. As showed in
Figure 2A, the CD spectra of all three peptide pairs dis-
played typical double minima at 208 and 222 nm, indicat-
ing the formation of the α–helical secondary structures.
Obviously, the α-helicity of MT-SC29EK/N36 complex
slightly increased as compared to that of SC29EK/N36
and C34/N36 complexes. The thermostability of each 6-
HBs, defined as the midpoint of the thermal unfolding
transition (Tm) value, was further measured. As shown
in Figure 2B, SC29EK-based 6-HB had a significantly
Figure 2 Helical stability of SC29EK and MT-SC29EK determined
by CD spectroscopy. The α-helicity (A) and thermostability (B) of
6-HB formed by a CHR peptide (SC29EK or SC29EK) and the NHR
peptide N36 are shown. Final concentration of each peptide in PBS
is 10 μM.
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HB (65.0°C), but the Tm value of MT-SC29EK-based 6-HB
was dramatically increased to 79.1°C, indicating that
addition of two M-T hook residues can dramatically en-
hance the thermal stability of 6-HB conformation.
High-affinity interactions of MT-SC29EK with the NHR
target
We then used the ITC technology to determine the
thermodynamic profiles of the molecular interaction be-
tween the inhibitors and N36. The heat released or
absorbed during the interaction allowed an accurate deter-
mination of the binding constant (K), reaction stoichiom-
etry (N), enthalpy (ΔH) and entropy (ΔS). As shown in
Figure 3, the formation of 6-HBs formed by SC29EK and
N36 or MT-SC29EK and N36 is a typical enthalpy-driven
reaction, in which a large amount of heat is released. Com-
pared to SC29EK, the K value of MT-SC29EK increased
4.7-folds (from 1.39 × 107 to 6.46 × 107 M−1), suggesting a
dramatically increased interacting-affinity. Together withthe CD data, we confirmed that the M-T hook residues
can dramatically fortify the binding affinity of peptide
inhibitors.
The M-T hook residues markedly increase the potency of
SC29EK to block 6-HB
Inhibition of CHR peptides on HIV-1 entry is through
binding to the exposed NHR thus competing off the
viral CHR, namely blocking 6-HB formation during
the fusion reaction. We previously developed a capture
ELISA-based approach to screen or evaluate the peptide
or small molecule-based fusion inhibitors [26], in which
the 6-HB-specific antibody NC-1 was coated to the
ELISA plate as a capture and the biotinylated-C34 was
used for a signal detection. Here, we compared the po-
tency of SC29EK and MT-SC29EK to physically block
the 6-HB formation. As shown in Figure 4, both peptides
were able to block the 6-HB at a dose dependant manner,
however, SC29EK had an IC50 of 14 μM whereas MT-
SC29EK had an IC50 value of 0.6 μM, indicating a 23-fold
increase. Therefore, the simple addition of two M-T hook
residues did confer the inhibitors with a high strength
to target the NHR, in line with the biophysical data de-
scribed above.
The M-T hook residues significantly improve the antiviral
activity of SC29EK
Based on its high binding to the NHR target and potent
inhibition on the 6-HB formation, we expected that MT-
SC29EK has an increased antiviral activity as compared
to SC29EK. In the single-cycle entry assay (Figure 5A),
SC29EK and MT-SC29EK inhibited HIV-1NL4–3 pseudo-
viruses with IC50 values of 2.2 ± 0.3 nM and 0.7 ± 0.0 nM
respectively, indicating a 3.1-fold increased potency for
MT-SC29EK. For the wild-type HIV-1NL4–3 replication
(Figure 5B), SC29EK had an IC50 of 0.9 ± 0.1 nM, whereas
MT-SC29EK had an IC50 of 0.2 ± 0.0 nM, indicating a 4.5-
fold increase. These results indicated that two M-T hook
residues can significantly enhance the anti-HIV activity of
SC29EK. In parallel, we also tested a panel of well-known
control peptides, including T20, C34, SFT, CP32M, T1249
and T2635 (Table 1). Promisingly, MT-SC29EK showed
the most potent inhibitory activity against HIV-1 fusion
and infection, highlighting its potential for clinical
development.
Potent activity of MT-SC29EK against T20- and
SC29EK-resistant HIV-1 variants
The mutations of T20-resistance have been largely mapped
to the peptide binding region in the NHR of gp41
[8,10,27]. We have recently showed that the M-T hook
residues can dramatically improve the potency of CHR
peptides to inhibit T20-resistant HIV-1 variants, which
carry single or double T20-resistant mutations [24,25].
Figure 3 Interaction affinity of SC29EK and MT-SC29EK with N36 measured by ITC assay. 1 mM N36 dissolved in double distilled H2O was
injected into the chamber containing 100 μM SC29EK (Left) or MT-SC29EK (Right). The experiments were carried out at 25°C. Data acquisition and
analysis were performed using MicroCal Origin software (version 7.0). The upper panels show the titration traces and the lower panels show the
binding affinity when the N36 solution was injected into the SC29EK or MT-SC29EK solution.
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MT-SC29EK for those HIV-1 mutants (Table 2). As shown
in Table 2, all the tested T20-resistant HIV-1 variants con-
ferred high cross-resistance to SC29EK; however, MT-
SC29EK retained high potency against these T20- and
SC29EK- resistant viruses. Notably, the single Q40H muta-
tion resulted in >25.4-fold resistance for T20 and 46.6-fold
resistance for SC29EK, but it did not affect the inhibitory
activity of MT-SC29EK. The similar phenotypes were also
observed for the I37T and V38A single mutations and the
V38A/Q42T double mutation, which rendered high re-
sistance to T20 and SC29EK but were highly sensitiveFigure 4 Inhibition of SC29EK and MT-SC29EK on 6-HB as
measured by ELISA. Data were derived from the results of 3
independent experiments and are expressed as means ± S.D.to MT-SC29EK. As compared to SC29EK, the inhibitory
activity of MT-SC29EK on various HIV-1 variants dra-
matically increased.
High-affinity binding of MT-SC29EK to the NHR mutants
To get insights how the M-T hook-modified inhibitors
possess high potency against drug-resistant HIV-1 vari-
ants, we continued to compare the binding affinity of
SC29EK and MT-SC29EK to the NHR mutants. A panel
of N36-based peptides carrying a single (I37T, V38A,
Q40H, N43K) or double (I37T/N43K and V38A/N42T)
NHR mutations were applied in the CD analysis. In most
cases, the NHR mutations resulted in an obvious decrease
in the thermal stability of SC29EK-based 6-HBs, such as
V38A (Tm = 62.1°C) and I37T/N43K (Tm = 61.1°C) mu-
tants, but addition of two hook residues could largely re-
cover the loss (Figure 6). In other words, the Tm values of
MT-SC29EK-based 6-HBs dramatically increased. There-
fore, the M-T hook residues could compensate the binding
affinity in the NHR mutants thus preserving the high
inhibitory activity against SC29EK- and T20-resistant
HIV-1 variants.
MT-SC29EK displays a high genetic barrier to the
development of resistance
We asked whether the M-T hook residues can confer
the inhibitors with a high genetic barrier to the develop-
ment of resistance. To address this, we performed the
in vitro selection of resistant HIV-1NL4–3 for SC29EK
and MT-SC29EK in parallel. As shown in Figure 7A, the
Figure 5 Anti-HIV activity of SC29EK and MT-SC29EK.
(A) Inhibition of HIV-1NL4–3 pseudovirus entry. (B) Inhibition of the
wild-type HIV-1NL4–3 replication. Data were derived from the results
of 3 independent experiments and are expressed as means ± S.D.
Table 1 Anti-HIV activity of MT-SC29EK and control
peptidesa
IC50 (nM)
Inhibitor Length (a.a.) Entry Replication
T20 36 73.2 ± 9.1 48.6 ± 1.2
C34 34 2.7 ± 0.1 1.3 ± 0.2
SFT 36 2.6 ± 0.1 1.5 ± 0.1
CP32M 32 1.8 ± 0.2 1.0 ± 0.2
T1249 39 1.4 ± 0.2 1.2 ± 0.2
T2635 38 1.1 ± 0.1 0.4 + 0.2
SC22EK 22 51.3 + 5.4 58.2 + 15.2
MT-SC22EK 24 2.1 ± 0.2 1.1 ± 0.1
SC29EK 29 2.2 ± 0.3 0.9 ± 0.2
MT-SC29EK 31 0.7 ± 0.0 0.2 ± 0.0
aThe data were derived from the results of three independent experiments
and expressed as means ± SD; a.a. means the number of amino acids.
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dose-escalating SC29EK. After 35 generations of passage
over 7 months, the concentration of SC29EK was raised
to 2,650 nM; in a sharp contrast, virus escape from in-
hibition by the MT-SC29EK peptide was much more dif-
ficult than escape from the SC29EK peptide.
We were surprised that it was much more difficult to se-
lect viruses resistant to the M-T hook-modified SC29EK in-
hibitor compared to unmodified inhibitor. To prove this
finding, we compared the short-peptide pair SC22EK and
MT-SC22EK for inducing the resistance, as our previous
studies demonstrated that the MT-SC22EK possessed a sig-
nificantly improved activity than SC22EK to inhibit both
wild-type and T20-resistant HIV-1 strains. Consistently, the
virus culture could be reasonably recovered after 22 pas-
sages in 4 months, wherein the concentration of SC22EK
was escalated up to as high as 8,000 nM (Figure 7B). How-
ever, MT-SC22EK only approached to 100 nM due to the
difficulty of the virus passage. These results implied that
the M-T hook-modified peptide inhibitors might possess a
dramatically increased genetic barrier to the development
of resistance.
Discussion
Previously, we identified that the heptad amino acid
motif (110QIWNNMT116) preceding the pocket-binding
domain of CHR-derived peptides could dramatically en-
hance the binding affinity and antiviral activity of inhibi-
tors [28]. Based on the QIWNNMT motif-containing
peptide CP621-652, we developed a potent HIV-1 fusion
inhibitor named CP32M [29]. However, we did not know
the molecular determinants underlying the stability and
anti-HIV activity of inhibitors in detail. Recently, we
solved the high-resolution crystal structure of CP621-
652 complexed by a NHR-derived peptide (T21) [23].
Surprisingly, we found the M-T hook structure, in which
the residue Thr116 redirects the peptide chain to pos-
ition Met115 above the left side of the hydrophobic
pocket on the NHR trimer and the side chain of Met115
caps the hydrophobic pocket to stabilize the interaction
between the pocket and the pocket-binding domain [23].
To directly define the structure and function of the M-T
hook, we generated the peptide MT-C34 by incorporat-
ing Met115 and Thr116 into the N-terminus of C34
[24]. The high resolution crystal structure of MT-C34
verified a universal structural feature for CHR-based in-
hibitors. We also demonstrated that addition of two
hook residues could dramatically enhance the binding
affinity and thermal stability of 6-HB core. Compared
with C34, MT-C34 exhibited the significantly increased
activity to inhibit HIV-1 fusion and replication [24].
These findings prompted us to propose a new strategy
for designing HIV-1 fusion inhibitors. Very recently, we
verified this concept by introducing the M-T hook
Table 2 Inhibitory activity of SC29EK and MT-SC29EK against T20-resistant HIV-1 variantsa
T20 SC29EK MT-SC29EK
HIV-1NL4–3 IC50 n-fold
b IC50 n-fold IC50 n-fold
WT 52.1 ± 8.5 1 1.8 ± 0.2 1 0.6 ± 0.1 1
I37T 552.2 ± 123.4 10.6 15.0 ± 0.3 8.3 0.8 ± 0.2 1.3
V38A 1842.6 ± 56.1 35.4 16.2 ± 1.9 9 0.6 ± 0.1 1
V38M 378.3 ± 41.7 7.3 15.1 ± 1.8 8.4 1.7 ± 0.0 2.8
Q40H 1321.5 ± 92.3 25.4 83.8 ± 10.8 46.6 0.8 ± 0.1 1.3
N43K 366.8 ± 47.4 7 >250 >138.9 7.2 ± 0.2 12
D36S/V38M 202.6 ± 12.6 3.9 11.7 ± 0.7 6.5 1.2 ± 0.0 2
I37T/N43K >2250 >43 >250 >138.9 21.2 ± 4.4 35.3
V38A/N42T >2250 >43 37.7 ± 6.4 20.9 0.6 ± 0.0 1





Figure 6 Binding stability of SC29EK and MT-SC29EK with N36 mutants determined by CD spectroscopy. (A) I37T; (B) V38A; (C) Q40H;
(D) N43K; (E) I37T/N43K; (F) V38A/N42T. Final concentration of each peptide in PBS is 10 μM.
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Figure 7 In vitro selection of HIV-1 resistant to fusion inhibitors.
(A) Induction of resistant HIV-1 with SC29EK and MT-SC29EK;
(B) Induction of resistant HIV-1 with SC22EK and MT-SC22EK. The
molecular clone of HIV-1NL4–3 was passaged in the presence of 1.5-2
fold escalating concentrations of peptides. One culture is shown as
a representative.
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served a significant optimization [25]. In the present study,
we selected SC29EK as a template to validate the general
role of the M-T hook structure, as this electrostatically
constrained helical peptide has a relatively short sequence
but possesses a potent antiviral activity thus having poten-
tial to be further developed for clinical use [20].
The initial structural data of gp41 6-HBs informed the
mechanisms of HIV-1 fusion and its inhibition [12-14].
The CHR-derived peptides act by competitive binding to
the exposed NHR during its conformational change to the
fusogenic state (i.e. pre-hairpin conformation) and thus
block the 6-HB formation in a dominant-negative fashion
[16,17]. It is generally thought that a high-affinity binding
is required for an exogenous peptide to compete off the
viral CHR thus critically determining the antiviral activity,
thereby a number of strategies have been explored to im-
prove the binding affinity of inhibitors [11,17-19,30]. Our
series of studies have provided a new approach that can
dramatically enhance the binding of inhibitors to the NHR
target [23-25,28,29]. The biophysical data presented hereindicated that the binding stability of MT-SC29EK could
be greatly increased as compared to that of SC29EK. It is
conceivable that two M-T hook residues may integrate the
pocket-binding domain thus synergistically enhancing the
interactions of MT-SC29EK with the targeting NHR re-
gion. Consistent to this hypothesis, MT-SC29EK could
physically block the 6-HB formation more efficiently
and possessed higher anti-HIV activity. Promisingly,
MT-SC29EK showed the most potent inhibition against
HIV-1 entry and replication as compared to the well-
characterized first- (T20, C34) and next- (T1249, SFT,
T2635) generations of HIV-1 inhibitors.
Like other classes of anti-HIV drugs, HIV-1 fusion inhib-
itors are also facing the problem of drug-resistance. The
emergence and spread of T20-resistant HIV-1 strains have
already resulted in increased number of patients failing to
treatment. T20-resistance has been predominantly mapped
to the substitutions in the amino acid 36–45 of the NHR,
with a contiguous three residues (G36-I37-V38) being
a hotspot [8-10,31,32]. Similar to SC34EK and SC29EK,
Sifuvirtide (SFT) was also designed by introducing multiple
salt-bridges into C34 [22]. Due to its potent anti-HIV ac-
tivity, SFT has already been advanced into Phase III clinical
trials in China and may become the second HIV-1 fusion
inhibitor for clinical use. However, SFT could easily induce
drug-resistance in the in vitro selection and HIV-1 variants
displayed high cross-resistance to T20 [33]. The in vitro
selection and resistant profiles of SC34EK and T2635 were
also reported [34,35]. Eggink et al. [36] described four
mechanisms of drug resistance: reduced contact, steric
obstruction, electrostatic repulsion, and electrostatic at-
traction. From SFT-resistance, we deduced several add-
itional mechanisms, such as hydrogen bond disruption
and hydrophobic contact disruption [33,37]. Therefore, an
ideal next-generation HIV-1 fusion inhibitor should ef-
ficiently inhibit the existing inhibitor-resistant HIV-1
variants but itself possessing a high genetic barrier to over-
come drug-resistance. Our studies suggested that the M-T
hook structure might confer the inhibitors these two fea-
tures. First, MT-SC29EK was able to potently inhibit a
panel of major T20-resistant HIV-1 variants, which also
displayed high-level cross-resistance to SC29EK. More im-
pressively, MT-SC29EK and its short version MT-SC22EK
suffered from the difficulty of inducing drug-resistance
during the in vitro selection, implying their considerable
higher genetic barriers than SC29EK or SC22EK to the de-
velopment of resistance. Very recently, we have found that
the M-T hook-modified C34 (MT-C34) and Sifuvirtide
(MT-SFT) behaved with a similar phenotype (unpublished
data). Taken together, we consider that the M-T hook
structure can render the peptide fusion inhibitors with a
high genetic barrier to select the resistant HIV-1 variants,
which provides an important feature for drug develop-
ment. It is well established that the residues involving
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ing HIV-1 evolution; the mutations of these residues are
often lethal to the virus. Thus, the balance between virus
survival and drug resistance becomes hard to maintain,
and the genetic barrier for drug resistance against the M-
T hook should increase [2,15]. Furthermore, it has been
shown that if the drug-target affinity is too high, the virus
does not escape by mutating the binding site, but by redu-
cing the window of opportunity for the drug to act
[19,21,35]. Definitely, more follow-up studies are required
to explore how the M-T hook structure can dramatically
increase the potency of inhibitors against the known re-
sistant HIV-1 variants and simultaneously confer a high
genetic barrier to resistance. Besides selecting the escape
viruses and mapping the responsible mutations, the mech-
anism of action by the M-T hook structure-modified in-
hibitors should be pursued in the context of the recently
solved Env trimer structure [38-40].
Conclusions
We demonstrated that two M-T hook residues have
greatly improved the antiviral profiles of SC29EK, verifying
the M-T hook structure as a general strategy for designing
or optimizing HIV-1 fusion inhibitor. The resulting inhibi-
tor MT-SC29EK has potent inhibitory activity against di-
verse HIV-1 strains and possesses a high genetic barrier to




A panel of CHR peptides including T20, C34, SFT,
CP32M, T1249, T2635, SC29EK, MT-SC29EK, SC22EK,
MT-SC22EK and the NHR peptide N36 and its mutants
(I37T, V38A, Q40H, N43K, I37T/N43K, and V38A/N42T)
were synthesized by a standard solid-phase FMOC method
as described previously [24]. All peptides were acetylated
at the N-terminus and amidated at the C-terminus and
purified by reversed-phase high-performance liquid chro-
matography (HPLC). They were verified for purity >95%
and correct amino acid composition by mass spectrom-
etry. Concentrations of the peptides were determined
by UV absorbance and a theoretically calculated molar-
extinction coefficient ε (280 nm) of 5500 M−1 · cm−1 and
1490 M−1 · cm−1 based on the number of tryptophan and
tyrosine residues, respectively [41].
Circular dichroism (CD) spectroscopy
CD spectroscopy was performed according to our proto-
cols described previously [26]. Briefly, a CHR peptide
(C34, SC29EK or MT-SC29EK) was incubated with an
equal molar concentration of N36 or its mutant (I37T,
V38A, Q40H, N43K, I37T/N43K, and V38A/N42T) at
37°C for 30 min. The final concentration of each peptidewas 10 μM in PBS buffer (pH 7.2). The CD spectra were
acquired on a Jasco spectropolarimeter (model J-815)
using a 1 nm bandwidth with a 1 nm step resolution
from 195 to 260 nm at room temperature. The spectra
were corrected by subtraction of a blank corresponding
to the solvent. Data were averaged over three accumula-
tions. The α-helical content was calculated from the CD
signal by dividing the mean residue ellipticity [θ] at
222 nm by the value expected for 100% helix formation
(−33,000 degrees.cm2.dmol−1). The thermal denaturation
experiment was performed by monitoring the change in
ellipticity [θ] at 222 nm at the increasing temperature
(20–98°C) using temperature controller. The temperature
was increased at a rate of 1.2°C per min; data were ac-
quired at a 1 nm bandwidth at 222 nm at a frequency of
0.25 Hz. The melting curve was smoothened, and the mid-
point of the thermal unfolding transition (Tm) values were
taken as the maximum of the derivative d [θ]222/dT. The
Tm value was detected at a peptide concentration of
10 μM in PBS buffer.
Isothermal Titration Calorimetry (ITC)
ITC assay was performed using an ITC200 Microcalorime-
ter instrument (MicroCal, USA) as described previously
[24]. In brief, 1 mM N36 dissolved in ddH20 was injected
into the chamber containing 100 μM SC29EK or MT-
SC29EK. The experiments were carried out at 25°C. The
time between injections was 240 s and the stirring speed
was 500 rpm. The heats of dilution were determined in
control experiments by injecting N36 into ddH20 and sub-
tracted from the heats produced in the corresponding
peptide-peptide binding experiments. Data acquisition
and analysis were performed using MicroCal Origin soft-
ware (version 7.0).
Inhibition of 6-HB formation by peptides
The 6-HB core-specific monoclonal antibody NC-1 was
obtained from Dr. Shibo Jiang in the New York Blood
Center (New York, NY) through the ARRRP, Division of
AIDS, NIAID, National Institute of Health. The inhibi-
tory activity of SC29EK or MT-SC29EK on the 6-HB for-
mation was measured by a modified ELISA as previously
described [26]. Briefly, a 96-well polystyrene plate was
coated with 2 μg/ml NC-1 in 0.1 M Tris buffer (pH 8.8).
A tested peptide at graded concentrations was mixed
with the biotinylated-C34 (0.1 μM) and incubated with
N36 (0.1 μM) at room temperature for 30 min. The mix-
ture was then added to the NC-1-coated plate, followed
by incubation for 30 min and washing with a washing
buffer (PBS containing 0.1% Tween 20) three times.
Then horseradish peroxidase (HRP)-labeled streptavidin
(Invitrogen) and the substrate 3,3,5,5- tetramethylbenzi-
dine (Sigma) were sequentially added. Absorbance at
450 nm (A450) was measured using an ELISA reader.
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The inhibition of peptides on the HIV-1 entry was deter-
mined by single-cycle infection assay as described pre-
viously [42]. Briefly, HIV-1 pseudovirus was generated
by cotransfecting 293 T cells with an Env-expressing plas-
mid and a backbone plasmid pSG3Δenv that encodes Env-
defective, luciferase-expressing HIV-1 genome. The super-
natants were harvested and filtered 48 h after transfection
and 50% tissue culture infectious dose (TCID50) was deter-
mined in TZM-bl cells. The peptides were prepared with
3-fold dilutions and mixed with 100 TCID50 viruses and
then incubated 1 h at room temperature. The mixture was
added to TZM-bl cells (104/well) and incubated 48 h at
37°C. The luciferase activity was measured using luciferase
assay reagents and a Luminescence Counter (Promega).
The inhibition of peptides on HIV-1 replication was
determined by a molecular cloned wild-type HIV-1NL4–3.
In brief, the virus stock was harvested and quantified
48 h post-transfection. 100 TCID50 viruses were used to
infect TZM-bl cells in the presence or absence of serially
diluted peptides. Two days post-infection, the cells were
harvested and lysed in reporter lysis buffer and the lucif-
erase activity was measured as described above.Induction of HIV-1 resistance to inhibitors
The in vitro selection of HIV-1 resistance to peptide inhib-
itors was performed as described previously [33]. Briefly,
MT-4 cells were seeded at 1 × 104 in RPMI 1640 medium
containing 10% fetal bovine serum on 12-well plates. The
molecular clone of HIV-1NL4–3 was used to infect the cells
in the presence or absence of diluted peptide inhibitors
(SC29EK, MT-SC29EK, SC22EK and MT-SC22EK). The
cells were incubated at 37°C with 5% CO2 until an exten-
sive cytopathic effect was observed. The culture superna-
tants were harvested and used for next passage on fresh
MT-4 cells with 1.5-2 fold increasing concentrations of
peptide. Cells and supernatant were harvested at regular
time points and stored at −80°C.
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